Abstrakt

Przypisy

• 1. Blake G.J., Ridker P.M.: Novel clinical markers of vascular wallinflammation. Circ. Res., 2001; 89: 763-771
  Google Scholar
• 2. Boirivant M., Leoni M., Tariciotti D., Fais S., Squarcia O., PalloneF.: The clinical significance of serum C reactive protein levels inCrohn’s disease. Results of a prospective longitudinal study. J. Clin.Gastroenterol., 1988; 10: 401-405
  Google Scholar
• 3. Canin-Endres J., Salky B., Gattorno F., Edye M.: Laparoscopicallyassisted intestinal resection in 88 patients with Crohn’s disease.Surg. Endosc., 1999; 13: 595-599
  Google Scholar
• 4. Chamouard P., Richert Z., Meyer N., Rahmi G., Baumann R.: Diagnosticvalue of C-reactive protein for predicting activity levelof Crohn’s disease. Clin. Gastroenterol. Hepatol., 2006; 4: 882-887
  Google Scholar
• 5. Chardavoyne R., Flint G.W., Pollack S., Wise L.: Factors affectingrecurrence following resection for Crohn’s disease. Dis. Colon Rectum,1986; 29: 495-502
  Google Scholar
• 6. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., KornbluthA., Rachmilewitz D., Lichtiger S., D’Haens G., Diamond R.H.,Broussard D.L., Tang K.L., van der Woude C.J., Rutgeerts P.; SONICStudy Group: Infliximab, azathioprine, or combination therapy forCrohn’s disease. N. Engl. J. Med., 2010; 362: 1383-1395
  Google Scholar
• 7. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B.,Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J.D., PollackP.F.: Adalimumab for maintenance of clinical response and remissionin patients with Crohn’s disease: the CHARM trial. Gastroenterology,2007; 132: 52-65
  Google Scholar
• 8. Consigny Y., Modigliani R., Colombel J.F., Dupas J.L., Mary J.Y.:Biological markers of short term relapse in Crohn’s disease (CD).Gastroenterology, 2001; 120 (Suppl. 1): A141
  Google Scholar
• 9. Fagan E.A., Dyck R.F., Maton P.N., Hodgson H.J., Chadwick V.S.,Petrie A., Pepys M.B.: Serum levels of C-reactive protein in Crohn’sdisease and ulcerative colitis. Eur. J. Clin. Invest., 1982; 12: 351-359
  Google Scholar
• 10. Ford E.S., Giles W.H., Myers G.L., Rifai N., Ridker P.M., ManninoD.M.: C-reactive protein concentration distribution among US childrenand young adults: findings from the National Health and NutritionExamination Survey, 1999-2000. Clin. Chem., 2003; 49: 1353-1357References
  Google Scholar
• 11. Gasche C., Scholmerich J., Brynskov J., D’Haens G., Hanauer S.B.,Irvine E.J., Jewell D.P., Rachmilewitz D., Sachar D.B., Sandborn W.J.,Sutherland L.R.: A simple classification of Crohn’s disease: report ofthe Working Party for the World Congresses of Gastroenterology,Vienna 1998. Inflamm. Bowel Dis., 2000; 6: 8-15
  Google Scholar
• 12. Greenfield J.R., Samaras K., Jenkins A.B., Kelly P.J., Spector T.D.,Gallimore J.R., Pepys M.B., Campbell L.V.: Obesity is an importantdeterminant of baseline serum C-reactive protein concentration inmonozygotic twins, independent of genetic influences. Circulation,2004; 109: 3022-3028
  Google Scholar
• 13. Henriksen M., Jahnsen J., Lygren I., Stray N., Sauar J., Vatn M.H.,Moum B.; IBSEN Study Group: C-reactive protein: a predictive factorand marker of inflammation in inflammatory bowel disease. Resultsfrom a prospective population-based study. Gut, 2008; 57: 1518-1523
  Google Scholar
• 14. Jain S., Gautam V., Naseem S.: Acute-phase proteins: as diagnostictool. J. Pharm. Bioallied Sci., 2011; 3: 118-127
  Google Scholar
• 15. Karczewski J., Swora-Cwynar E., Rzymski P., Poniedziałek B.,Adamski Z.: Selected biologic markers of inflammation and activityof Crohn’s disease. Autoimmunity, 2015; 48: 318-327
  Google Scholar
• 16. Kiss L.S., Papp M., Lovasz B.D., Vegh Z., Golovics P.A., Janka E.,Varga E., Szathmari M., Lakatos P.L.: High-sensitivity C-reactive proteinfor identification of disease phenotype, active disease, and clinicalrelapses in Crohn’s disease: a marker for patient classification?Inflamm. Bowel Dis., 2012; 18: 1647-1654
  Google Scholar
• 17. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El YafiF.A., Belaiche J.: Behaviour of Crohn’s disease according to the Viennaclassification: changing pattern over the course of the disease.Gut, 2001; 49: 777-782
  Google Scholar
• 18. Maachi M., Piéroni L., Bruckert E., Jardel C., Fellahi S., HainqueB., Capeau J., Bastard J.P.: Systemic low-grade inflammation is relatedto both circulating and adipose tissue TNFα, leptin and IL-6 levelsin obese women. Int. J. Obes. Relat. Metab. Disord., 2004; 28: 993-997
  Google Scholar
• 19. Mekhjian H.S., Switz D.M., Watts H.D., Deren J.J., Katon R.M.,Beman F.M.: National Cooperative Crohn›s Disease Study: factorsdetermining recurrence of Crohn›s disease after surgery. Gastroenterology,1979; 77: 907-913
  Google Scholar
• 20. Murphy T.M., Baum L.L., Beaman K.D.: Extrahepatic transcriptionof human C-reactive protein. J. Exp. Med., 1991; 173: 495-498
  Google Scholar
• 21. Poullis A.P., Zar S., Sundaram K.K., Moodie S.J., Risley P., TheodossiA., Mendall M.A.: A new, highly sensitive assay for C-reactiveprotein can aid the differentiation of inflammatory bowel disordersfrom constipation- and diarrhoea-predominant functional boweldisorders. Eur. J. Gastroenterol. Hepatol., 2002; 14: 409-412
  Google Scholar
• 22. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F.: The Montrealclassification of inflammatory bowel disease: controversies,consensus, and implications. Gut, 2006; 55: 749-753
  Google Scholar
• 23. Saverymuttu S.H., Hodgson H.J., Chadwick V.S., Pepys M.B.: Differingacute phase responses in Crohn’s disease and ulcerative colitis.Gut, 1986; 27: 809-813
  Google Scholar
• 24. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O.O.,Hanauer S.B., McColm J., Bloomfield R., Sandborn W.J.; PRECISE 2Study Investigators: Maintenance therapy with certolizumab pegolfor Crohn’s disease. N. Engl. J. Med., 2007; 357: 239-250
  Google Scholar
• 25. Shine B., Berghouse L., Jones J.E., Landon J.: C-reactive protein asan aid in the differentiation of functional and inflammatory boweldisorders. Clin. Chim. Acta, 1985; 148: 105-109
  Google Scholar
• 26. Tall A.R.: C-reactive protein reassessed. N. Engl. J. Med., 2004;350: 1450-1452
  Google Scholar
• 27. Vermeire S., Van Assche G., Rutgeerts P.: C-reactive proteinas a marker for inflammatory bowel disease. Inflamm. Bowel Dis.,2004; 10: 661-665
  Google Scholar

Pełna treść artykułu